Venmax Drugs & Pharmaceuticals delivered remarkable financial performance in the June 2026 quarter, with net profit surging 200% to ₹0.12 crore compared to ₹0.04 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a substantial improvement in the company's bottom-line performance during the quarter ended June 2026.
The company's revenue growth was equally impressive, with sales rising 104.96% to ₹2.48 crore in the quarter ended June 2026, as reported by Business Standard. This compares to sales of ₹1.21 crore during the same quarter in the previous year, indicating robust demand for the company's pharmaceutical products and services.
The company's operating profit margin (OPM) stood at 4.84% during the quarter ended June 2026, as reported by Business Standard. Additionally, PBDT (Profit Before Depreciation and Tax) and PBT (Profit Before Tax) both increased by 200% to ₹0.12 crore each, reflecting the company's strong operational performance across all key financial metrics during the quarter.
